| K-number | K243937 |
| Device name | Accuro 3S |
| Applicant | Rivanna Medical, Inc. |
| Product code | IYO |
| Device class | Class II |
| Decision date | May 23, 2025 |
| Decision | Substantially Equivalent |
| Regulation | 892.1560 |
The Accuro 3S is a portable diagnostic ultrasound imaging system for use by qualified healthcare professionals in hospitals or medical clinics. It provides B-mode imaging and includes SpineNav-AI machine learning software to assist with musculoskeletal imaging and guidance for procedures like neuraxial anesthesia.
The Accuro 3S features a Dual-Array convex transducer probe with two side-by-side PZT-based arrays (64 elements each, 3.5–4.0 MHz center frequency) that compound images into a single sector-scan format, compared to the predicate's mechanically scanned single-element transducer. SpineNav-AI uses deep convolutional neural networks for anatomical segmentation, whereas the predicate's SpineNav3D uses analytical template-matching algorithms. The system includes an integrated battery, touchscreen interface, and DICOM-based archival workflows.
IEC 60601-1, IEC 60601-1-2, IEC 60601-1-6, IEC 60601-2-37, IEC 62304, IEC 62366-1, IEC 62359, ISO 10993-1, ISO 14971, NEMA UD 2-2004, NEMA PS 3.1–3.20e (DICOM), and AAMI TIR69:2017.
Accuro 3S shares the same intended use, user population, and clinical applications (musculoskeletal imaging and neuraxial anesthesia guidance) as the predicate Accuro. Although the transducer geometry differs (Dual-Array versus mechanically scanned), non-clinical testing including acoustic output, safety compliance, and performance validation confirms no new risks. SpineNav-AI, while using machine learning instead of template matching, was validated on 120 test sequences from diverse demographics with per-frame accuracy of 82.1–99.3% and meets established success criteria; this methodology parallels the reference device Venue's cNerve feature. Together these findings support that the technological differences do not affect safety or effectiveness for the intended indications.
View the full FDA submission: accessdata.fda.gov